Ruel, Michael D <br/><br/>
Using race in clinical research to develop tailored medications. Is the FDA encouraging discrimination or eliminating traditional disparities in health care for African Americans?  [electronic resource] 

 -  The Journal of legal medicine  Jun 2006 
 - 225-41 p.  digital 
<br/><br/> Publication Type: Journal Article; Legal Case 
<br/><br/><label>ISSN: </label>0194-7648 
<br/><br/><label>Standard No.: </label>10.1080/01947640600716457  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Black or African American--genetics<br/>Clinical Protocols<br/>Clinical Trials as Topic--legislation & jurisprudence<br/>Drug Approval--legislation & jurisprudence<br/>Drug Combinations<br/>Drug Industry--economics<br/>Drugs, Investigational<br/>Heart Failure--drug therapy<br/>Humans<br/>Hydralazine--therapeutic use<br/>Isosorbide Dinitrate--therapeutic use<br/>Patient Selection<br/>Pharmacogenetics--legislation & jurisprudence<br/>Prejudice<br/>Socioeconomic Factors<br/>Supreme Court Decisions<br/>Treatment Outcome<br/>United States<br/>United States Food and Drug Administration<br/>Vasodilator Agents--therapeutic use